<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03383978</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2016-000225-39</org_study_id>
    <nct_id>NCT03383978</nct_id>
  </id_info>
  <brief_title>Intracranial Injection of NK-92/5.28.z (HER2.taNK) Cells in Patients With Recurrent HER2-positive Glioblastoma (Quilt 3.C001)</brief_title>
  <acronym>CAR2BRAIN</acronym>
  <official_title>Single Center, Open Label, Phase I Study of Intracranial Injection of NK-92/5.28.z (HER2.taNK) Cells in Patients With Recurrent HER2-positive Glioblastoma (Quilt 3.C001)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DRK Blutspendedienst Baden-Württemberg-Hessen gGmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Georg-Speyer-Haus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>LOEWE Center for Cell and Gene Therapy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NantKwest, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this clinical study is to evaluate the safety and tolerability of
      NK-92/5.28.z (HER2.taNK) and to determine the maximum tolerated dose or maximum feasible dose
      (MFD). Recommended phase 2 doses both for intraoperative injections only (RP2Diio) and
      repetitive injections (RP2Dri) will be determined. Frequent side effects and target organs of
      toxicity and their severity, duration and reversibility will be determined. Furthermore,
      pharmacokinetics and pharmacodynamics will be examined. In addition, potential signs of
      anti-tumor activity of NK-92/5.28.z cells will be analyzed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.03.</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) or maximum feasible dose (MFD).</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Period of detectability of NK-92/5.28.z cells in blood and cerebrospinal fluid (CSF) during the first 24 weeks after NK-92/5.28.z application with qPCR.</measure>
    <time_frame>24 weeks</time_frame>
    <description>qPCR detection of NK-92/5.28.z in blood or CSF</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytokine profile in the blood and the cerebrospinal fluid.</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>NK-92- and/or CAR 5.28.z-directed immune response.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>NK-92/5.28.z (HER2.taNK)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intracranial application of NK-92/5.28.z (HER2.taNK), 1x10E7-1x10E8</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NK-92/5.28.z (HER2.taNK)</intervention_name>
    <description>Intracranial application of NK-92/5.28.z (HER2.taNK), 1x10E7-1x10E8</description>
    <arm_group_label>NK-92/5.28.z (HER2.taNK)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Recurrent or refractory HER2-positive glioblastoma or its variant gliosarcoma in which
             a relapse surgery (partial or total) is being planned.

          2. Prior therapy must include the standard of care for glioblastoma (radiotherapy plus
             concomitant and adjuvant chemotherapy with temozolomide according to the EORTC 26981
             trial).

          3. Age ≥ 18 years.

          4. Life expectancy ≥ 3 months.

          5. Bilirubin ≤ 3x normal, AST ≤ 5x normal, ALT ≤ 5x, serum creatinine ≤ 2x upper limit of
             normal for age, leukocyte count 3/nl, thrombocyte count 100/nl and Hb 8.0 g/dl.

          6. Blood oxygenation of 90% as measured by pulse oximetry on room air.

          7. Women must have a negative serum pregnancy test within 72h prior to the start of the
             first NK-92/5.28.z cell injection.

          8. Sexually active patients must be willing to utilize effective birth control methods
             throughout the study and for 24 weeks after the last NK-92/5.28.z cell injection. This
             includes two different forms of effective contraception (e.g. hormonal contraceptive
             and condom, IUD/IUS and condom) or sterilization.

          9. Patients should have been off other antineoplastic therapy for two weeks prior to
             entry in this study. Temozolomide will be allowed up to 48h preinjection. At the the
             time of inclusion, dexamethasone up to a total dose of 4 mg per day will be allowed if
             medically indicated.

         10. Informed consent explained to and signed by patient; patient given copy of informed
             consent.

         11. Karnofsky performance score of ≥ 50%.

        Exclusion Criteria:

          1. Previous anti-angiogenic therapy e.g. with bevacizumab (Avastin).

          2. Coagulation disorder (INR&gt;1.4 or PTT&gt;50sec) or anticoagulation at therapeutic dosage.

          3. Active autoimmune disease.

          4. Patients with clinical or laboratory signs for immunodeficiency or under
             immunosuppressive medication other than corticosteroids.

          5. Severe intercurrent infection.

          6. Known HIV, HBV or HCV positivity.

          7. Chronic heart failure NYHA ≥III.

          8. Patients with a prior solid organ transplantation or allogenic haematopoietic stem
             cell transplantation.

          9. Unable to undergo MRI.

         10. Pregnancy or breastfeeding.

         11. Drug or alcohol abuse.

         12. Severe psychiatric disorder which might interfere with the study treatment or
             examination.

         13. Simultaneous participation in another clinical trial. If a subject participated in a
             trial testing another IMP, such IMP should have been terminated at least 30 days
             before inclusion of the subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael C Burger, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johann W. Goethe University Hospital, Frankfurt am Main, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael C Burger, Dr. med.</last_name>
    <phone>0049696301</phone>
    <phone_ext>87711</phone_ext>
    <email>michael.burger@kgu.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Johann W. Goethe University Hospital, Department of Neurosurgery</name>
      <address>
        <city>Frankfurt</city>
        <zip>60528</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Senft, Prof. Dr. med.</last_name>
      <phone>0049696301</phone>
      <phone_ext>5295</phone_ext>
      <email>christian.senft@kgu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johann W. Goethe University Hospital, Senckenberg Institute of Neurooncology</name>
      <address>
        <city>Frankfurt</city>
        <zip>60528</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael C Burger, Dr. med.</last_name>
      <phone>0049696301</phone>
      <phone_ext>87711</phone_ext>
      <email>michael.burger@kgu.de</email>
    </contact>
    <contact_backup>
      <last_name>Joachim P Steinbach, Prof. Dr. med.</last_name>
      <phone>0049696301</phone>
      <phone_ext>87711</phone_ext>
      <email>joachim.steinbach@med.uni-frankfurt.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.kgu.de/neuroonkologie</url>
    <description>Sponsor homepage</description>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2017</study_first_submitted>
  <study_first_submitted_qc>December 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 27, 2017</study_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospital</investigator_affiliation>
    <investigator_full_name>Michael Burger</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

